REPRO-MED Systems (KRMD) Receives a Buy from Lake Street

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

It Looks Like KORU Medical Systems, Inc.'s (NASDAQ:KRMD) CEO May Expect Their Salary To Be Put Under The Microscope

Craig-Hallum Sticks to Their Buy Rating for REPRO-MED Systems (KRMD)

KORU Medical Systems Inc (KRMD) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...

KORU Medical Systems Inc (KRMD) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic Growth Initiatives

REPRO-MED Systems: Strong Start to Fiscal Year 2024 with Strategic Growth and Consistent Margins

Q1 2024 KORU Medical Systems Inc Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

KORU Medical Systems Inc (KRMD) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Challenges

KORU Medical Systems GAAP EPS of -$0.04 in-line, revenue of $8.2M beats by $0.67M

KORU Medical Systems Inc (KRMD) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Challenges

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review